Abstracts tagged "Biomarkers"

Abstract Number: 298 • 2016 ACR/ARHP Annual Meeting
Disease Progression in Osteoarthritis Is Driven By Multiple Disease Parameters Leading to Comparable Levels of Joint Destruction
Anne C. Bay-Jensen¹, Asger Bihlet², Inger Byrjalsen², Jeppe Andersen³, Christian S. Thudium⁴, Bente J. Riis², Claus Christiansen², Hans Guehring⁵, Martin Michaelis⁵, Christoph Ladel⁵ and Morten Asser Karsdal⁶, ¹Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark, ³Clinical Development, Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁵Merck KGaA, Darmstadt, Germany, ⁶Rheumatology, Nordic Bioscience, Herlev, Denmark
Background/Purpose: There is a need for successful drug development in osteoarthritis (OA) as there are currently no disease modifying drugs approved for OA. This may…
Abstract Number: 914 • 2016 ACR/ARHP Annual Meeting
Longitudinal Blood Transcriptomics Uncovers Immune Networks Associated with Complications in Lupus Pregnancy
Seunghee Hong¹, Romain Banchereau¹, Marta M. Guerra², Jane E. Salmon^3,4 and Virginia Pascual¹, ¹Baylor Institute for Immunology Research, Baylor Research Institute, Dallas, TX, ²Department of Medicine and Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: SLE is a systemic autoimmune disease that predominantly affects women in reproductive years. SLE pregnancies result in higher rates of adverse outcomes compared with…
Abstract Number: 1652 • 2016 ACR/ARHP Annual Meeting
Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial
Natasja Stæhr Gudman¹, Pernille Juhl², Christian S. Thudium³, Anne Sofie Siebuhr⁴, Inger Byrjalsen⁵, Morten Asser Karsdal⁴ and Anne C. Bay-Jensen⁴, ¹Nordic Bioscience A/S, Herlev, Denmark, ²Biomarkers & Research, Nordic Bioscience, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular disease, consequent to vascular and endothelial dysfunction, which…
Abstract Number: 2136 • 2016 ACR/ARHP Annual Meeting
CD14 Deficiency Delays Progression of Cartilage Degeneration and Protects Against Early Deficits in Functional Outcomes in a Murine Osteoarthritis Model
Nisha Sambamurthy^1,2, Vu Nguyen^1,2, Ryan Smalley^2,3, George R. Dodge^3,4 and Carla R. Scanzello^1,2,3, ¹Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Translational Musculoskeletal Research Center, CMC Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Orthopedic Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Research, CMC Veterans Affairs Medical Center, Philadelphia, PA
Background/Purpose: CD14, though expressed by multiple cell types, is highly expressed by monocytes and macrophages. It forms a complex with Toll-like receptors (TLRs), particularly TLR-2…
Abstract Number: 2619 • 2016 ACR/ARHP Annual Meeting
Sustained Suppression of Peripheral Biomarkers By Mavrilimumab but Not Golimumab in Anti-Tumor Necrosis Factor-Inadequate Responders: An Exploratory Analysis in the Phase IIb Earth Explorer 2 Clinical Trial
Xiang Guo¹, Shiliang Wang¹, Anne C. Bay-Jensen², Morten Asser Karsdal², A Godwood³, Marius Albulescu³, D Close³, Patricia C. Ryan¹, Lorin Roskos⁴ and Wendy White¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Rheumatology, Nordic Bioscience, Herlev, Denmark, ³MedImmune, Cambridge, United Kingdom, ⁴MedImmune, LLC, Mountain View, CA
Background/Purpose: Treatment of rheumatoid arthritis (RA) patients by anti-tumour necrosis factors (anti-TNFs), such as golimumab, has improved patient outcomes. However, unmet therapeutic needs exist for…
Abstract Number: 3089 • 2016 ACR/ARHP Annual Meeting
Predicting the Response to TNF Inhibition or B Cell Depletion Therapy from Peripheral Whole Blood Gene Expression Profiles in Patients with Rheumatoid Arthritis
Duncan Porter¹, C. S. Goodyear², J. S. Nijjar¹, Martina Messow³, Stefan Siebert¹, Manikhandan Mudaliar⁴ and Iain B. McInnes⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom, ⁴Glasgow Polyomics Facility, University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain
Background/Purpose: The ORBIT study demonstrated that rituximab is non-inferior to a TNFi-first strategy in biologic naive, sero-positive patients with active RA over 12 months (Lancet…
Abstract Number: 380 • 2016 ACR/ARHP Annual Meeting
Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis
AnneMarie Brescia¹, Megan Simonds², Suzanne McCahan³, Tim Bunnell³, Kathleen E. Sullivan⁴ and Carlos D. Rosé¹, ¹Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ²Nemours, Nemours Biomedical Research, Wilmington, DE, ³Nemours Biomedical Research, Wilmington, DE, ⁴Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The goal of this project is the identification of informative synovial biomarkers to predict which children with oligoarticular juvenile idiopathic arthritis (JIA) will have…
Abstract Number: 966 • 2016 ACR/ARHP Annual Meeting
Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response
Gaurav Gulati¹, Michael Bennett², Khalid Abulaban^3,4, Qing Ma⁵, Marisa S. Klein-Gitelman⁶, Kelly A. Rouster-Stevens⁷, Christopher Haffner⁵, Kasha Wiley⁸, Stacy P. Ardoin⁹, Jun Ying¹⁰, Prasad Devarajan¹¹ and Hermine I. Brunner⁸, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Helen DeVos Children's Hospital, Grand Rapids, MI, ⁵Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁶Div of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/NW University, Chicago, IL, ⁷Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ⁸Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ¹⁰Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ¹¹Dept of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH
Renal Activity In Lupus (RAIL) Urinary Biomarkers Predict Treatment Response Background/Purpose: We have previously demonstrated the strong predictive value of the Renal Activity In Lupus…
Abstract Number: 1656 • 2016 ACR/ARHP Annual Meeting
Compare the Potential of Osteoclast Precursors (OCPs) Residing in Bone Marrow and Peripheral Blood As the Surrogates of Psoriasis Pathogenesis
Yahui Grace Chiu¹, Edward Schwarz², Dongge Li³, Nelson Huertas³, Cristy Bell⁴, Debbie Campbell⁴ and Christopher T. Ritchlin⁵, ¹Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Orthopedeatrics, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bone marrow (BM) is not only the place where osteoclast precursors (OCPs) are derived from, but also the major reservoirs of OCPs. Current data…
Abstract Number: 2291 • 2016 ACR/ARHP Annual Meeting
Impact of Plasma Urate and Tophaceous Burden on Inflammatory Biomarkers of Cardiovascular Disease
John FitzGerald¹, Benjamin D. Levine², Jennifer Raymond³ and Maureen A. McMahon¹, ¹Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Gout and hyperuricemia have been associated with cardiovascular disease. Studies have documented the impact of serum urate levels on hypertension and that increased urate…
Abstract Number: 2622 • 2016 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics, and Biomarker Profile from Phase 1 Clinical Trials of Healthy Volunteers Treated with GDC-0853, a Highly Selective Reversible Oral Bruton’s Tyrosine Kinase (BTK) Inhibitor
Tamiko Katsumoto, Helen Winter, Shweta Kotwal, Elaine Murray, Rui Zhao, Marilyn Florero, Alyse Lin, Anita Moein, Rena Wang, Meire Bremer, Serika Kokubu, Adrian Serone, Alyssa Morimoto, Leslie Chinn and Ann Herman, Genentech, Inc., South San Francisco, CA
Background/Purpose: B cell depletion therapy has provided evidence of the importance of B cells in the pathogenesis of rheumatoid arthritis and other inflammatory diseases. Consequently,…
Abstract Number: 3091 • 2016 ACR/ARHP Annual Meeting
Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate
Cem Gabay¹, Jérôme Msihid², Nikki Daskalakis³, Neil Graham⁴, Anne Barbot⁵, Moshe Zilberstein³ and Anita Boyapati⁴, ¹University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland, ²Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, NJ, France, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, France
Background/Purpose: Patients with RA develop bone and joint damage due to chronic inflammation that is mediated by a destructive synovial pannus.1 The pannus is composed…
Abstract Number: 383 • 2016 ACR/ARHP Annual Meeting
Potential Biomarkers of Disease Activity in Juvenile Idiopathic Arthritis – Data from the Portuguese Register, Reuma.Pt
Ana Filipa Mourão^1,2,3, MJ Santos⁴, Mónica Eusébio⁵, Ana Lopes⁶, Filipa Ramos⁷, Manuel Salgado⁸, Paula Estanqueiro⁹, Jose Antonio Melo Gomes¹⁰, Fernando Magalhaes Martins¹¹, José Antonio Costa¹², Ana Carolina Furtado¹³, Ricardo Figueira¹⁴, Iva Brito^15,16,17, Jaime Branco^18,19, João E. Fonseca²⁰ and Helena Canhão²¹, ¹NOVA Medical School - Faculdade Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal, ²Centro Hospitalar Lisboa Ocidental (CHLO- E.P.E.), Lisbon, Portugal, ³Rheumatology, Instituto de Medicina Molecular, Lisbon, Portugal, ⁴Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ⁵Sociedade Portuguesa de Reumatologia, LIsboa, Portugal, ⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ⁷Rheumatology and Metabolic Bone Diseases Department, Santa Maria Hospital,CHLN, Lisbon, Portugal, ⁸Pediatrics, Centro Hospitalar de Coimbra, Coimbra, Portugal, ⁹Pediatrics, Centro Hospitalar da Universidade de Coimbra, Coimbra, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Portuguese Society of Rheumatology, Lisbon, Portugal, ¹²Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ¹³Rheumatology, Hospital do Divino Espírito Santo, Ponta Delgada, São Miguel, Portugal, ¹⁴Rheumatology, Hospital Dr. Nélio Mendonça, Funchal, Portugal, ¹⁵Rheumatology, Centro Hospitalar do Pirto, Hospital de São João, Porto, Portugal, ¹⁶Rua Raul Caldevilla 126-2 Dto, Hospital Sao Joao, Porto, Portugal, ¹⁷Faculdade de Medicina da Universidade do Porto, Porto, Portugal, ¹⁸Rheumatology, CHLO, Hospital Egas Moniz, Lisbon, Portugal, ¹⁹CEDOC, Nova Medical School, Lisbon, Portugal, ²⁰Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, Lisboa, Portugal, ²¹Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal
, IL6, IL10, IL17 and TNF in patients with JIA, and detect their relation to disease activity. Results: 281 patients, 66% female, mean age 17.3±10…
Abstract Number: 999 • 2016 ACR/ARHP Annual Meeting
Utility of Neutrophil CD64 Expression & sTREM-1 in Distinguishing Bacterial Infection from Disease Flare in SLE and ANCA Associated Vasculitis
Sajal Ajmani, Harshit Singh, Saurabh Chaturvedi, Mohit kumar Rai and Vikas Agrawal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Fever is a common presenting manifestation of systemic lupus erythematosus (SLE) and ANCA associated vasculitis (AAV). Treating physician is challenged to differentiate between disease…
Abstract Number: 1657 • 2016 ACR/ARHP Annual Meeting
Soluble Biomarkers May Differentiate Psoriatic Arthritis from Osteoarthritis
Vinod Chandran¹, Anthony V. Perruccio², Suzanne Li³, Fatima Abji⁴, Rajiv Gandhi⁵ and Dafna D Gladman⁶, ¹Medicine, Krembil Research Institute, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University Health Network, Arthritis Program, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: It is often difficult to differentiate psoriatic arthritis (PsA) from osteoarthritis (OA) in clinical practice. To aid clinical diagnosis, we aimed to identify soluble…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].